Ask most trust board members where research sits in their organisation and you'll usually be pointed towards the R&D office, somewhere down a corridor. That answer is starting to look out of date.
Research is being written into NHS planning in a way it hasn't been before. From April 2026, part of NIHR funding has been tied to performance, and research is now formally part of NHS medium term planning. For the people who run estates, workforce, finance and data, that shift matters more than it might first appear.
The bottleneck has moved
The headline news is good. According to the latest government figures, the average time to set up a commercial clinical trial fell from 169 days to 122 days when comparing the six months to March 2026 with the same period a year earlier. That beats the 150-day target Prime Minister Sir Keir Starmer set in April 2025, to be met by March 2026. Combined review by the MHRA and HRA, standard contracts and less duplicated paperwork did a lot of the heavy lifting.
Here's the thing, though. Those were largely national fixes. With approvals moving faster, the remaining delays sit closer to home: a pharmacy team with no spare capacity to handle trial medicines, a clinic room booked solid, a research nurse post that has been vacant since spring. NHS England's own board paper was candid that the system had been consistently missing its speed indicators even as regulatory timelines improved. None of that gets solved in Whitehall. It gets solved in rota planning and space allocation meetings.
Trust in the evidence starts upstream
Innovation that reaches patients is only as sound as the evidence underneath it, and that evidence has a long supply chain. Before anything is trialled in people, it passes through years of laboratory work that depends upon the quality and traceability of the materials used. A study built on a mislabelled compound or an untested batch can mislead everyone who later relies on it.
That is why batch-level documentation has become a basic expectation in laboratory supply, and some vendors now publish third-party test certificates for every lot, like research peptides that are labelled for research use only, including GLP-1 analogues, and it posts lot-specific certificates of analysis. Its products are not licensed medicines in the UK and are not intended for human use. As public interest in peptide therapies grows, keeping that distinction clear between research materials and licensed treatment is something NHS organisations and their partners will need to communicate plainly.
The same principle applies to data. As the new Health Data Research Service opens NHS records to researchers at scale, trusts will be asked how their data was collected, coded and governed. Boards that can answer that confidently will be more attractive partners for the studies that follow.
Commercial research is still an under-used asset
The awkward part of the story is recruitment. The ABPI's latest clinical trials report found that just 3.4% of trial participants in England in 2024/25 were recruited into industry trials in the NHS, a share that has fallen sharply since 2017/18.
That matters financially as well as clinically. Industry studies bring income into trusts, pay for research staff and give patients access to treatments years before they might otherwise arrive. In my view, a trust that treats commercial research as a distraction from waiting lists has the sums the wrong way round. Handled well, it brings in money and specialist people, and it offers patients another route when standard options have run out.
Who gets to take part
Speed and volume aren't the whole picture. Research that mostly reaches patients near large teaching hospitals will produce evidence that fits those patients best. Ipsos research cited by the ABPI found 58% of UK adults say they would be willing to join a clinical trial, falling to 41% among people from ethnic minority backgrounds.
This is where community and neighbourhood health teams come in. Trust is built locally, through GPs, pharmacists, community groups and familiar faces. Taking studies closer to where people live, through community diagnostic centres, mobile units or primary care networks, widens who benefits. It also makes the findings more useful for the populations ICBs are actually responsible for.
What leaders can do now
None of this needs a new strategy document. It needs a handful of ordinary decisions made with research in mind.
Estates teams can protect clinical space for research rather than letting it be the first thing borrowed during a busy winter. Workforce leads can build research time into job plans for nurses, pharmacists and allied health professionals as well as consultants. Finance directors can track commercial trial income properly and reinvest it where it was earned, so departments see a return on the effort. Digital and information governance teams can get ahead of the new clinical trials regulations, which came into force in April 2026 and will reward organisations that can move quickly and report reliably.
And boards can ask for research performance alongside the usual elective and urgent care numbers. What gets reported tends to get resourced.
The decade ahead
The UK has spent years talking about becoming a better place to do research. The national plumbing is finally improving. What happens next depends less on ministers and more on whether individual organisations decide that research is part of their day job.
My hunch is that the trusts which make that call early will find it easier to recruit staff, keep them and bring new treatments to their patients sooner. That seems like a future worth planning for.
